Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 10/31
(Values in U.S. thousands)
| 10-2025 | 10-2024 | 10-2023 | 10-2022 | 10-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,244 | 1,271 | 915 | 12,360 | 29,128 |
| Marketable Securities | 13,930 | 18,653 | 22,929 | 17,327 | 6,599 |
| Receivables | N/A | 173 | 270 | 46 | N/A |
| TOTAL | $15,887 | $21,362 | $25,356 | $30,200 | $36,003 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 193 | 229 | 166 | 212 | 254 |
| TOTAL | $193 | $229 | $166 | $212 | $254 |
| Total Assets | $16,080 | $21,591 | $25,522 | $30,412 | $36,257 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 165 | 525 | 206 | 265 | 136 |
| Accrued Expenses | 1,761 | 1,946 | 1,770 | 1,726 | 1,095 |
| TOTAL | $1,967 | $2,500 | $2,028 | $2,037 | $1,270 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 264 | 347 | 242 | 351 | 394 |
| TOTAL | $163 | $203 | $123 | $175 | $220 |
| Total Liabilities | $2,130 | $2,703 | $2,151 | $2,212 | $1,490 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 33,377 | 32,197 | 31,700 | 30,921 | 30,132 |
| Common Shares | 330 | 322 | 311 | 309 | 301 |
| Retained earnings | -251,677 | -240,750 | -228,196 | -218,385 | -204,790 |
| Other shareholders' equity | -1,211 | -1,116 | -966 | -847 | -671 |
| TOTAL | $13,950 | $18,888 | $23,371 | $28,200 | $34,767 |
| Total Liabilities And Equity | $16,080 | $21,591 | $25,522 | $30,412 | $36,257 |